AR070411A1 - Forma polimorfica de n-[3-terc-butil-1-(3-cloro-4-hidroxifenil)-1h-pirazol-5-il]-n'-{2-[(3-{2-[(2-hidroxietil)sulfanil]fenil}[1,2,4]triazolo[4,3-a]piridin-6-il)sulfanil]bencil}urea, composiciones farmaceuticas que la comprenden y metodo de preparacion - Google Patents
Forma polimorfica de n-[3-terc-butil-1-(3-cloro-4-hidroxifenil)-1h-pirazol-5-il]-n'-{2-[(3-{2-[(2-hidroxietil)sulfanil]fenil}[1,2,4]triazolo[4,3-a]piridin-6-il)sulfanil]bencil}urea, composiciones farmaceuticas que la comprenden y metodo de preparacionInfo
- Publication number
- AR070411A1 AR070411A1 ARP090100349A ARP090100349A AR070411A1 AR 070411 A1 AR070411 A1 AR 070411A1 AR P090100349 A ARP090100349 A AR P090100349A AR P090100349 A ARP090100349 A AR P090100349A AR 070411 A1 AR070411 A1 AR 070411A1
- Authority
- AR
- Argentina
- Prior art keywords
- sulfanil
- triazolo
- chloro
- phenyl
- urea
- Prior art date
Links
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 title 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- 239000004202 carbamide Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 abstract 2
- VGEXRDWWPSGZDH-UHFFFAOYSA-N 1-[5-tert-butyl-2-(3-chloro-4-hydroxyphenyl)pyrazol-3-yl]-3-[[2-[[3-[2-(2-hydroxyethylsulfanyl)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-6-yl]sulfanyl]phenyl]methyl]urea Chemical compound C=1C=C(O)C(Cl)=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)NCC1=CC=CC=C1SC(=CN12)C=CC1=NN=C2C1=CC=CC=C1SCCO VGEXRDWWPSGZDH-UHFFFAOYSA-N 0.000 abstract 1
- 238000004922 13C solid-state nuclear magnetic resonance spectroscopy Methods 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000006073 displacement reaction Methods 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
Abstract
Esta forma polimorfa es util en el tratamiento de varios trastornos, particularmente en el tratamiento de trastornos inflamatorios tales como la enfermedad pulmonar obstructiva cronica. Reivindicacion 1: La forma polimorfa B de N-[3-terc-butil-1-(3-cloro-4-hidroxifenil)-1H-pirazol-5-il]-N'-{2-[(3-{2-[(2-hidroxietil)sulfanil]fenil}[1,2,4]triazolo[4,3-a]piridin-6-il)sulfanil]bencil}urea que muestra desplazamientos a aproximadamente 155,4, 146,2, 144,3, 116,6, 42,5 y 35,2 ppm cuando se caracteriza por 13C RMN de estado solido referenciado a un estándar externo de adamantano cristalino, fijándose la resonancia a campos altos a 29,5 ppm.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2587908P | 2008-02-04 | 2008-02-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070411A1 true AR070411A1 (es) | 2010-04-07 |
Family
ID=40911989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100349A AR070411A1 (es) | 2008-02-04 | 2009-02-03 | Forma polimorfica de n-[3-terc-butil-1-(3-cloro-4-hidroxifenil)-1h-pirazol-5-il]-n'-{2-[(3-{2-[(2-hidroxietil)sulfanil]fenil}[1,2,4]triazolo[4,3-a]piridin-6-il)sulfanil]bencil}urea, composiciones farmaceuticas que la comprenden y metodo de preparacion |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8222273B2 (es) |
| EP (1) | EP2303267B1 (es) |
| JP (1) | JP5344942B2 (es) |
| KR (2) | KR20130087048A (es) |
| CN (1) | CN101939320B (es) |
| AR (1) | AR070411A1 (es) |
| AU (1) | AU2009211072B2 (es) |
| BR (1) | BRPI0907463A2 (es) |
| CA (1) | CA2712574C (es) |
| CY (1) | CY1114389T1 (es) |
| DK (1) | DK2303267T3 (es) |
| ES (1) | ES2423991T3 (es) |
| IL (1) | IL206948A (es) |
| MX (1) | MX2010008535A (es) |
| NZ (1) | NZ587094A (es) |
| PL (1) | PL2303267T3 (es) |
| PT (1) | PT2303267E (es) |
| RU (1) | RU2448966C1 (es) |
| SI (1) | SI2303267T1 (es) |
| TW (1) | TWI391391B (es) |
| WO (1) | WO2009098612A2 (es) |
| ZA (1) | ZA201005137B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| WO2012030645A1 (en) | 2010-08-30 | 2012-03-08 | Pulmatrix, Inc. | Respirably dry powder comprising calcium lactate, sodium chloride and leucine |
| AU2011296343B2 (en) | 2010-08-30 | 2015-12-10 | Pulmatrix Operating Company, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
| ES2710537T3 (es) | 2010-09-29 | 2019-04-25 | Pulmatrix Operating Co Inc | Polvos secos catiónicos |
| WO2013052844A1 (en) | 2011-10-07 | 2013-04-11 | Pulmatrix, Inc. | Methods for treating and diagnosing respiratory tract infections |
| RU2586333C1 (ru) | 2011-12-09 | 2016-06-10 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Производные 4-гидрокси-1,2,3,4-тетрагидронафталин-1-ил-мочевины и их применение в лечении, среди прочего, заболеваний дыхательного тракта |
| CN105646484A (zh) * | 2016-03-01 | 2016-06-08 | 孙霖 | 晶型b及制备方法 |
| CN105693716A (zh) * | 2016-03-01 | 2016-06-22 | 孙霖 | 晶型a及制备方法 |
| GB201611712D0 (en) | 2016-07-02 | 2016-08-17 | Hvivo Services Ltd | Methods and compounds for the treatment or prevention of severe or persistent influenza |
| GB201721793D0 (en) | 2017-12-22 | 2018-02-07 | Hvivo Services Ltd | Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP990182A2 (en) | 1998-06-11 | 2000-02-29 | Du Pont Pharm Co | Crystalline efavirenz |
| TR200202103T2 (tr) * | 1998-11-20 | 2002-11-21 | Mitsubishi Chemical Corporation | ''5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri'' |
| KR20070033317A (ko) * | 2004-07-16 | 2007-03-26 | 유에스브이 리미티드 | 아토바퀴온의 신규한 다형체 및 이의 제조 방법 |
| AU2005273612B2 (en) * | 2004-08-12 | 2010-10-14 | Pfizer Inc. | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors |
| GB0418015D0 (en) * | 2004-08-12 | 2004-09-15 | Pfizer Ltd | New compounds |
-
2009
- 2009-01-28 US US12/865,889 patent/US8222273B2/en not_active Expired - Fee Related
- 2009-01-28 AU AU2009211072A patent/AU2009211072B2/en not_active Ceased
- 2009-01-28 PL PL09708402T patent/PL2303267T3/pl unknown
- 2009-01-28 PT PT97084024T patent/PT2303267E/pt unknown
- 2009-01-28 CA CA2712574A patent/CA2712574C/en not_active Expired - Fee Related
- 2009-01-28 KR KR1020137015900A patent/KR20130087048A/ko not_active Withdrawn
- 2009-01-28 RU RU2010132639/04A patent/RU2448966C1/ru not_active IP Right Cessation
- 2009-01-28 WO PCT/IB2009/050351 patent/WO2009098612A2/en not_active Ceased
- 2009-01-28 DK DK09708402.4T patent/DK2303267T3/da active
- 2009-01-28 KR KR1020107016846A patent/KR101422318B1/ko not_active Expired - Fee Related
- 2009-01-28 EP EP09708402.4A patent/EP2303267B1/en not_active Not-in-force
- 2009-01-28 SI SI200930680T patent/SI2303267T1/sl unknown
- 2009-01-28 BR BRPI0907463A patent/BRPI0907463A2/pt not_active IP Right Cessation
- 2009-01-28 ES ES09708402T patent/ES2423991T3/es active Active
- 2009-01-28 CN CN2009801041294A patent/CN101939320B/zh not_active Expired - Fee Related
- 2009-01-28 NZ NZ587094A patent/NZ587094A/en not_active IP Right Cessation
- 2009-01-28 MX MX2010008535A patent/MX2010008535A/es active IP Right Grant
- 2009-02-02 JP JP2009021286A patent/JP5344942B2/ja not_active Expired - Fee Related
- 2009-02-03 AR ARP090100349A patent/AR070411A1/es unknown
- 2009-02-03 TW TW098103398A patent/TWI391391B/zh not_active IP Right Cessation
-
2010
- 2010-07-12 IL IL206948A patent/IL206948A/en not_active IP Right Cessation
- 2010-07-19 ZA ZA2010/05137A patent/ZA201005137B/en unknown
-
2013
- 2013-08-14 CY CY20131100704T patent/CY1114389T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070411A1 (es) | Forma polimorfica de n-[3-terc-butil-1-(3-cloro-4-hidroxifenil)-1h-pirazol-5-il]-n'-{2-[(3-{2-[(2-hidroxietil)sulfanil]fenil}[1,2,4]triazolo[4,3-a]piridin-6-il)sulfanil]bencil}urea, composiciones farmaceuticas que la comprenden y metodo de preparacion | |
| NO20083567L (no) | Hydantoinderivater for behandling av inflammatoriske forstyrrelser | |
| MX346101B (es) | Sonda de formacion de imagen de tau. | |
| NI201100006A (es) | Derivados de triazol útiles para el tratamiento de enfermedades. | |
| ECSP14013221A (es) | Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento. | |
| EA201170251A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ | |
| MX2011008501A (es) | Compuestos heterociclicos fusionados que contienen nitrogeno y su uso como inhibidores de la produccion de beta-amiloide. | |
| UY29840A1 (es) | Compuestos de pirimidina amida como inhibidores de pgds | |
| MX347706B (es) | Derivados de triazol y su uso para trastornos neurologicos. | |
| ATE531711T1 (de) | Für die behandlung von autoimmunerkrankungen und entzündlichen erkrankungen geeignete tetrahydrocyclopentaäbüindol-3- ylcarbonsäurederivate | |
| NO20091489L (no) | Tiazolpyrazolopyridiner som CRF1 reseptorantagonister | |
| ECSP088813A (es) | Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2 | |
| WO2010018109A3 (en) | Substituted aminotetralines | |
| BR112015009649A2 (pt) | composto de triazolo | |
| NO20091858L (no) | Hydrobenzamid derivater som inhibitorer av HSP90 | |
| ATE538100T1 (de) | Aminotetrahydroindazoloessigsäuren | |
| Darwish et al. | Development of novel 2, 4-bispyridyl thiophene–based compounds as highly potent and selective Dyrk1A inhibitors. Part I: benzamide and benzylamide derivatives | |
| NO20083708L (no) | 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer | |
| MX350862B (es) | Acidos de piperidinil naftilacetico. | |
| ATE476193T1 (de) | Immunstimulatorisches verfahren | |
| WO2011089396A3 (en) | Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen | |
| JP2012523429A5 (es) | ||
| NZ592740A (en) | Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof | |
| WO2018071315A3 (en) | Piperidine derivatives as liver x receptor beta agonists, compositions, and their use | |
| FR2961803B1 (fr) | Compositions acides pour l'elimination des oxalates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |